LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$14.71
+0.50 (+3.52%)
Open$14.00
Previous Close$14.21
Day High$15.09
Day Low$13.95
52W High$45.00
52W Low$9.28
Volume—
Avg Volume200.2K
Market Cap360.46M
P/E Ratio—
EPS$-12.98
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+90.0% upside
Current
$14.71
$14.71
Target
$27.95
$27.95
$18.45
$27.95 avg
$35.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 58.5K | 777.9K | 107.82M |
| Net Income | -447,264,559 | -5,352,900,307 | -16,079,673 |
| Profit Margin | -762,355.6% | -724,237.8% | -14.9% |
| EBITDA | -420,238,483 | -5,308,863,814 | -19,078,562 |
| Free Cash Flow | — | — | -8,704,547 |
| Rev Growth | -92.5% | -92.5% | +2.1% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |